GRCL Wutah bathi EPS kuartalan Gracell Biotechnologies Inc.

Gracell Biotechnologies (GRCL) is recognized as a leader in CAR-T cell engineering via its FasTCAR platform for the treatment of hematological malignancies. The quarterly EPS growth rate reflects current dynamics, where 69.40 characterizes this valuation parameter. While the company is scaling tests through contract manufacturers, high costs and therapy safety risks may delay the business from reaching break-even.

Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan Gracell Biotechnologies Inc. (GRCL): kanggo periode 04.07.2022 - 03.03.2024

Gracell (GRCL) - rincian metrik lan laporan keuangan

- rega saham lan prakiraan rega para ahli:

Rega saham Gracell Biotechnologies Inc.|GRCL - Target konsensus

- data kapitalisasi pasar:

Kapitalisasi pasar Gracell Biotechnologies Ltd|GRCL - Total Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Aset Bersih saben Siji Saham Gracell Biotechnologies|GRCL - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku gracellbio.com|GRCL - Aset Agregat Perusahaan

- data liabilitas lan likuiditas perusahaan:

Rasio Total Utang marang Ekuitas Gracell Biotechnologies|GRCL - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Gracell Biotechnologies|GRCL - Tanggungan utang total perusahaan|Utang-utang marang kapitalisasi buku Gracell Biotechnologies Ltd|GRCL - Utang jangka dawa|Utang jangka cendhak perusahaan Gracell Biotechnologies|Rasio cepet gracellbio.com

- rincian bathi lan kelipatan pasar:

GRCL - Penghasilan resik perusahaan|Bathi mangsa ngarep Gracell Biotechnologies|GRCL - Nilai perusahaan marang bathi resik|Prakiraan rega marang bathi Gracell Biotechnologies Ltd|GRCL - Rasio nilai perusahaan marang wutah bathi|Pangali EV/EBITDA Gracell Biotechnologies Ltd|GRCL - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Gracell Biotechnologies|GRCL - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan gracellbio.com|GRCL - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Gracell Biotechnologies

- informasi babagan volume dodolan lan pendapatan:

GRCL - Pendapatan lan volume dodolan|Prakiraan pendapatan perusahaan Gracell Biotechnologies Inc.|GRCL - Rasio rega marang dodolan|Multiplikator forward rega marang pendapatan Gracell Biotechnologies Ltd

Analisis fundamental perusahaan:Gracell Biotechnologies Inc. - GRCL

The recognition of Gracell Biotechnologies (GRCL) as a cell therapy leader following its acquisition by a pharma behemoth shifts the valuation of its assets into a realm of high market confidence. The quarterly earnings per share history, featuring the value 69.40, daily bridges the information gap between reports by measuring net income dynamics to identify overpayment risks during rallies or recovery potential during downturns.

Analisis perusahaan pesaing